Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1994 Nov;113(3):741–748. doi: 10.1111/j.1476-5381.1994.tb17056.x

Failure of CGS15943A to block the hypotensive action of agonists acting at the adenosine A3 receptor.

M Patel 1, M J Sheehan 1, P Strong 1
PMCID: PMC1510471  PMID: 7858863

Abstract

1. Adenosine receptor agonists were evaluated for their activity at the putative adenosine A3 receptor which mediates a 'xanthine-resistant' hypotensive response in the anaesthetized rat. The compounds tested were: the A1/A3 receptor agonist, N-[2-(4-aminophenyl)ethyl]adenosine (APNEA), the non-selective adenosine receptor agonist, 5'-N-ethylcarboxamidoadenosine (NECA), the adenosine A1 receptor-selective agonists, N-[(1S,trans)-2-hydroxycyclopentyl]adenosine (GR79236) and N6-cyclopentyl adenosine (CPA), the A2a receptor-selective agonists, 2-[[2-[4-(2-carboxyethyl) phenyl] ethyl] amino]-N- ethylcarboxamidoadenosine (CGS21680) and 2-phenylaminoadenosine (CV1808), and the moderately A2b selective agonist, N-[(2-methylphenyl)methyl]adenosine (metrifudil). 2. In confirmation of literature findings, APNEA (1-1000 nmol kg-1) induced hypotension and bradycardia; the hypotension was not blocked by pretreatment with the xanthine antagonist, 8-P-sulphophenyltheophylline (8-sPT; 40 mg kg-1, i.v.), whereas the bradycardia was attenuated. The non-xanthine antagonist, 9-fluoro-2-(2-furyl)-5,6-dihydro [1,2,4]triazolo[1,5-c]- quinazin-5-imine (CGS15943A; 3 mg kg-1 i.v.), also attenuated the bradycardia without affecting the hypotension. 3. The adenosine A1 receptor-selective agonists, GR79236 and CPA, both produced dose-dependent falls in blood pressure and heart rate which were antagonized by 8-sPT (40 mg kg-1) and CGS15943A (3 mg kg-1). 4. The adenosine A2a receptor-selective agonists, CGS21680 and CV1808, produced only a hypotensive response which was antagonized by 8-sPT (40 mg kg-1) and to a much greater extent by CGS15943A (3 mg kg-1), consistent with the response being mediated solely by A2a receptors.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
745

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Carruthers A. M., Fozard J. R. Effect of pertussis toxin treatment on the putative adenosine A3 receptor-mediated hypotensive response in the rat. Eur J Pharmacol. 1993 Nov 30;250(1):185–188. doi: 10.1016/0014-2999(93)90641-t. [DOI] [PubMed] [Google Scholar]
  2. Fozard J. R., Carruthers A. M. Adenosine A3 receptors mediate hypotension in the angiotensin II-supported circulation of the pithed rat. Br J Pharmacol. 1993 May;109(1):3–5. doi: 10.1111/j.1476-5381.1993.tb13522.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Fozard J. R., Carruthers A. M. The cardiovascular effects of selective adenosine A1 and A2 receptor agonists in the pithed rat: no role for glibenclamide-sensitive potassium channels. Naunyn Schmiedebergs Arch Pharmacol. 1993 Feb;347(2):192–196. doi: 10.1007/BF00169266. [DOI] [PubMed] [Google Scholar]
  4. Ghai G., Francis J. E., Williams M., Dotson R. A., Hopkins M. F., Cote D. T., Goodman F. R., Zimmerman M. B. Pharmacological characterization of CGS 15943A: a novel nonxanthine adenosine antagonist. J Pharmacol Exp Ther. 1987 Sep;242(3):784–790. [PubMed] [Google Scholar]
  5. Gurden M. F., Coates J., Ellis F., Evans B., Foster M., Hornby E., Kennedy I., Martin D. P., Strong P., Vardey C. J. Functional characterization of three adenosine receptor types. Br J Pharmacol. 1993 Jul;109(3):693–698. doi: 10.1111/j.1476-5381.1993.tb13629.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Linden J., Taylor H. E., Robeva A. S., Tucker A. L., Stehle J. H., Rivkees S. A., Fink J. S., Reppert S. M. Molecular cloning and functional expression of a sheep A3 adenosine receptor with widespread tissue distribution. Mol Pharmacol. 1993 Sep;44(3):524–532. [PubMed] [Google Scholar]
  7. Merkel L. A., Rivera L. M., Colussi D. J., Perrone M. H., Smits G. J., Cox B. F. In vitro and in vivo characterization of an A1-selective adenosine agonist, RG14202. J Pharmacol Exp Ther. 1993 May;265(2):699–706. [PubMed] [Google Scholar]
  8. Salvatore C. A., Jacobson M. A., Taylor H. E., Linden J., Johnson R. G. Molecular cloning and characterization of the human A3 adenosine receptor. Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):10365–10369. doi: 10.1073/pnas.90.21.10365. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Waelbroeck M., Camus J., Tastenoy M., Feifel R., Mutschler E., Tacke R., Strohmann C., Rafeiner K., Rodrigues de Miranda J. F., Lambrecht G. Binding and functional properties of hexocyclium and sila-hexocyclium derivatives to muscarinic receptor subtypes. Br J Pharmacol. 1994 Jun;112(2):505–514. doi: 10.1111/j.1476-5381.1994.tb13102.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Williams M., Francis J., Ghai G., Braunwalder A., Psychoyos S., Stone G. A., Cash W. D. Biochemical characterization of the triazoloquinazoline, CGS 15943, a novel, non-xanthine adenosine antagonist. J Pharmacol Exp Ther. 1987 May;241(2):415–420. [PubMed] [Google Scholar]
  11. Zhou Q. Y., Li C., Olah M. E., Johnson R. A., Stiles G. L., Civelli O. Molecular cloning and characterization of an adenosine receptor: the A3 adenosine receptor. Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7432–7436. doi: 10.1073/pnas.89.16.7432. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES